A B ST R A CT In man and other animals, urinary excretion of the histidine and histamine metabolite, imidazoleacetate, is increased and that of its conjugated metabolite, ribosylimidazoleacetate, decreased by salicylates. Imidazoleacetate has been reported to produce analgesia and narcosis. Its accumulation as a result of transferase inhibition could play a part in the therapeutic effects of salicylates. To determine the locus of salicylate action, we have investigated the effect of anti-inflammatory drugs on imidazoleacetate phosphoribosyl transferase, the enzyme that catalyzes the ATP-dependent conjugation of imidazoleacetate with phosphoribosylpyrophosphate. As little as 0.2 mM aspirin produced 50% inhibition of the rat liver transferase. In vivo, a 30% decrease in the urinary excretion of ribosylimidazoleacetate has been observed with plasma salicylate concentrations of 0.4 mM. The enzyme was also inhibited by sodium salicylate but not by salicylamide, sodium gentisate, aminopyrine, phenacetin, phenylbutazone, or indomethacin. The last four drugs have been shown previously not to alter the excretion of ribosylimidazoleacetate when administered in vivo. Since both the drug specificity and inhibitory concentrations are similar in vivo and in vitro, it seems probable that the effect of salicylates on imidazoleacetate conjugation results from inhibition of imidazoleacetate phosphoribosyl transferase.
INTRODUCTION
A principal urinary metabolite of L-histidine (1) and histamine (2) (3) (4) (5) (6) in humans and other species is 1-ribosylimidazole-4-acetate, which is formed by conjugation of imidazole-4 (5)-acetate with phosphoribosylpyroReceived for publication 21 November 1975 and in rezised form 2 February 1976. phosphate in an ATP-dependent reaction (7, 8) . In our previous studies (9) , administration of therapeutic doses of salicylates in humans resulted in a decrease in the urinary excretion of ribosylimidazoleacetate with a concomitant increase in the excretion of free imidazoleacetate. Because of the reported analgesic and narcotic action of imidazoleacetate (10, 11) and the possibility that salicylates may exert their analgesic effects through alteration in the metabolism of imidazoleacetate, we have investigated further the locus of salicylate action. [3H]Imidazoleacetic acid, 1.3 Ci/mmol, prepared from unlabeled imidazoleacetic acid by catalytic exchange with tritium gas, was purified by thin layer chromatography (9) and stored in solution, 1 was purchased from Amersham/Searle Corp., Arlington Heights, Ill. Unlabeled histamine metabolites were obtained from sources described earlier (9) . Acid phosphatase (potato, grade B) was obtained from Calbiochem, San Diego, Calif. and pyruvate kinase from Sigma Corporation, San Diego, Calif.
Purification of imidazoleacetate phosphoribosyl transferase. Male Osborne Mendel rats were anesthetized with ether. A midline abdominal incision was made, the portal vein catheterized, and the inferior vena cava severed. The portal vein was flushed with 0.25 M sucrose containing 50 mM Tris (Cl-), pH 7.5. After decapitation of the rat, the liver was excised, minced finely with a razor blade, and homogenized (10 strokes) with a tight-fitting ground-glass homogenizer in 5 volumes of 20 mM potassium phosphate, 5 mM MgClI, 1 mM EDTA, pH 7.5, at 0-4'C. The homogenate was filtered through two layers of cheesecloth and centrifuged at 100,000 g for 40 min. The supernatant fraction was stirred with an equal volume of DEAE-cellulose which had been previously equilibrated with 5 mM potassium phosphate, 1 mM EDTA, pH 7.0. After centrifugation at 5,000 g for 30 min, the supernatant fraction was discarded. The DEAE-cellulose was then washed three times by stirring with 5 volumes of the same buffer for 30 min. The washed DEAE-cellulose was extracted with 5 volumes of 1 mM EDTA in 0.5 mM potassium phosphate buffer, pH 7.0, for 30 min and the extract centrifuged at 5,000 rpm for 10 min to remove cellulose fibers. The enzyme was prepared on the day of the experiment.
Assay of imidazoleacetate phosphoribosyl transferase. The standard assay mixture contained 0.4 mM imidazoleace- (Fig. 2) . The inhibition was proportional to the concentration of aspirin: -0.2 mM aspirin caused 50% inhibition of the transferase. Beaven et al. (9) observed 30% inhibition of ribosylimidazoleacetate excretion in vivo with plasma concentrations of 0.38 mM and 50% inhibition with 0.7 mM aspirin (Fig. 3) . Purification of the transferase beyond the initial centrifugation step was not required to demonstrate the effect of aspirin on enzymatic activity. With crude transferase preparations, however, addition of ribose-5-phosphate or an ATP regenerating system was necessary to observe formation of the ribosylated product. When both were present the yield of phosphoribosylimidazoleacetate was increased. The inhibition of transferase activity by aspirin was apparent, whether the various components of the regenerating systems were added singly or in combination (Table I) . Effect of salicylates and other nonsalicylate anti-inflammatory drugs. Significant inhibition of the transferase was noted with aspirin and sodium salicylate, both of which were found to be effective inhibitors of ribosylimidazoleacetate excretion in vivo (9) . The salicylate derivative, salicylamide, which did not decrease ribosylimidazoleacetate excretion in vivo, did not inhibit the transferase reaction in vitro (Table II) . The salicylate metabolite, sodium gentisate, was also without effect on the transferase. Nonsalicylate anti-inflammatory drugs, *such as phenacetin, aminopyrine, phenylbutazone, and indomethacin, which were inactive in vivo, did not inhibit the reaction in vitro (Table II) . DISCUSSION The question arises whether inhibition of imidazoleacetate phosphoribosyl transferase is metabolically signifi- (7), are approximately the same as those in plasma (13) (14) (15) and since 50% inhibition of the transferase is observed with 0.25 mM ('-5 mg/100 ml) salicylate (Fig. 2) , it seems likely that ribose conjugation would be impaired by therapeutic doses of salicylates. Aspirin also inhibits prostaglandin synthetases from many species and tissues (Table III) . The ID50 of aspirin found with the prostaglandin synthetase from various preparations varied from one-fifth to more than 20 times that observed for the liver transferase in the present study. As noted above, nonsalicylate agents such as indomethacin and phenylbutazone, which are very effective inhibitors of prostaglandin synthetase (16, 18) , had no effect on imidazoleacetate phosphoribosyl transferase (Table II) (24) . Since aspirin and sodium salicylate were equipotent in inhibiting the transferase, acetylation is presumably not involved in the inhibition. Aside from its effects on platelet aggregation and the transferase, aspirin has several other inhibitory actions (Table III) . Among these are inhibition of (a) protein synthesis by rat liv-er preparations (20) , (b) protein and DNA synthesis during blast transformation of human lymphocytes (21, 25, 26) , and (c) bacterial growth (22) . The ID5o for aspirin in the transferase reaction was of the same magnitude as those noted for (a), (b), and (c), (Table III) .
The effect of aspirin on L-histidine metabolism may be of clinical importance, since this amino acid is the principal source of imidazoleacetate (1) . Although it has often been assumed that imidazoleacetate is pharmacologically inactive (see, for example, 27), it does have pronounced central effects. In the mouse, which conjugates imidazoleacetate poorly,' imidazoleacetic acid, in doses of 200 Ag/g intraperitoneally, produces prolonged narcosis and analgesia (10, 11; and confirmed in this laboratory). The analgesic effects of salicylates may in part be due to an accumulation of imidazoleacetate, although this has not been determined as yet.
